trial_id stringlengths 11 11 | source stringclasses 3
values | subsidiary stringlengths 2 68 | sponsor stringlengths 2 105 | official_title stringlengths 16 598 ⌀ | success_prediction float64 0 1 | economic_effect float64 0 1 | duration_prediction float64 -6.13 18.5k | success_composite float64 0.01 1 |
|---|---|---|---|---|---|---|---|---|
NCT00001373 | delisted | Merck Sharp & Dohme L.L.C. | Merck Sharp & Dohme LLC | An Exploratory Study Of The Genetics, Pathophysiology, And Natural History Of Autoinflammatory Diseases | 0.71 | 0.28 | 9,611 | 0.455019 |
NCT00002028 | listed | BRISTOL MYERS SQUIBB | Bristol-Myers Squibb | A Treatment Ind (Investigational New Drug) Protocol For The Use Of Videx (2',3'-Dideoxyinosine, Ddi) In Patients With Acquired Immunodeficiency Syndrome (Aids) Or Aids- Related Complex (Arc) Who Are Intolerant To Zidovudine (Retrovir) | 0.58 | 0.47 | 2,844 | 0.481771 |
NCT00002029 | listed | Abbott | Abbott | Long-Term Nutritional Support In Patients With The Acquired Immunodeficiency Syndrome: Comparison Of Liposyn Iii 2 Percent With Liposyn Ii 20 Percent | 0.61 | 0.34 | 3,398 | 0.450425 |
NCT00002035 | listed | BRISTOL MYERS SQUIBB | Bristol-Myers Squibb | Double-Blind Comparison Of The Efficacy Of Continued Zidovudine Versus 2',3'-Dideoxyinosine (Ddi) (Bmy-40900) For The Treatment Of Patients With Aids Or Aids-Related Complex And Increasing Symptomatology Despite Treatment With Zidovudine | 0.94 | 0.7 | 4,294 | 0.755877 |
NCT00002036 | listed | Abbott | Abbott | Phase I Safety Study Of Anti-Hiv Immune Serum Globulin (Human) | 0.39 | 0.12 | 3,398 | 0.267301 |
NCT00002041 | listed | BRISTOL MYERS SQUIBB | Bristol-Myers Squibb | Evaluation Of Amphotericin B In The Treatment Of Biopsy Proven Candida Esophagitis In Immunocompromised Patients | 0.32 | 0.16 | 2,891 | 0.227168 |
NCT00002057 | listed | BRISTOL MYERS SQUIBB | Bristol-Myers Squibb | Nystatin Pastilles For The Prevention Of Oral Candidiasis In Patients With Aids Or Arc | 0.33 | 0.06 | 2,891 | 0.198664 |
NCT00002067 | listed | Bristol-Myers Squibb | Bristol-Myers Squibb | Phase III Randomized Double-Blind Study Comparing Megestrol Acetate at 800 mg/Day, and Placebo in AIDS Patients With Anorexia and Cachexia | 0.9 | 0.62 | 2,059.48 | 0.811573 |
NCT00002168 | listed | BRISTOL MYERS SQUIBB | Bristol-Myers Squibb | An Open Label, Randomized, Comparative Study Of Zerit (D4T) + Videx (Ddi) + Crixivan Versus Retrovir (Azt) + Epivir (3Tc) + Crixivan In Hiv-Infected, Antiretroviral Naive Subjects With Cd4 Cell Counts Of 200 - 700/Mm3 And Hiv Rna Baseline Copy Number Of >= 10,000 Copies/Ml | 0.93 | 0.6 | 2,891 | 0.725409 |
NCT00002176 | listed | BRISTOL MYERS SQUIBB | Bristol-Myers Squibb | A Pilot Open Label Trial Of Hiv Therapy With D4T (Stavudine), Ddi (Didanosine), Nelfinavir And Hydroxyurea In Subjects With Early Asymptomatic Hiv Infection | 0.74 | 0.52 | 4,181 | 0.580992 |
NCT00002177 | listed | BRISTOL MYERS SQUIBB | Bristol-Myers Squibb | A Pilot Open Label Trial Of Hiv Therapy With D4T (Stavudine), Ddi (Didanosine), Nelfinavir And Hydroxyurea In Subjects With Recent Hiv Infection | 0.8 | 0.29 | 120 | 0.579622 |
NCT00002188 | listed | Ligand Pharmaceuticals | Ligand Pharmaceuticals | Phase Ii Evaluation Of Oral Alrt1057 In Patients With Aids-Related Kaposi'S Sarcoma. | 0.35 | 0.17 | 2,061 | 0.303753 |
NCT00002201 | listed | Abbott | Abbott | Safety And Efficacy Of Ritonavir (Abt-538) In Combination With Nelfinavir In Hiv-Infected Subjects. | 0.62 | 0.33 | 3,398 | 0.452706 |
NCT00002207 | listed | Bristol-Myers Squibb | Bristol-Myers Squibb | A Randomized, Double-Blind Study of the Antiviral Activity of Once-Daily and Twice-Daily Dosing of Didanosine in Combination With Twice-Daily Dosing of Stavudine in HIV-Infected Subjects | 0.92 | 0.77 | 823.11 | 0.825658 |
NCT00002223 | listed | Abbott | Abbott | Ritonavir (Abt-538)/Indinavir Combination Treatment In Hiv-Infected Patients Previously Receiving Indinavir 800 Mg Tid | 0.94 | 0.51 | 3,398 | 0.696696 |
NCT00002224 | listed | BRISTOL MYERS SQUIBB | Bristol-Myers Squibb | Comparison Of Hiv Rna Suppression Produced By Triple Regimens Containing Either Didanosine Enteric Coated Or Didanosine Formulations Each Administered Once Daily | 0.96 | 0.87 | 1,062 | 0.91325 |
NCT00002234 | listed | DuPont Industrial Biosciences USA, LLC | Dupont Applied Biosciences | A Phase Ii, 48 Week, Open-Label Study Designed To Evaluate The Efficacy, Safety, Tolerability, And Pharmacokinetics Of A Simplified Dosing Regimen Of Preveon (Adefovir Dipivoxil; Bis-Pom Pmea), Videx (Didanosine; Ddi), Sustiva (Efavirenz; Dmp-266), And Epivir (Lamivudine; 3Tc) Administered Once Daily For The Treatment ... | 0.93 | 0.54 | 1,394 | 0.759039 |
NCT00002235 | listed | AGOURON PHARMACEUTICALS | Agouron Pharmaceuticals | A Phase Ii, 48-Week, Open-Label Study Designed To Evaluate The Safety, Tolerability, And Efficacy Of A Simplified Dosing Regimen Of Viracept (Nelfinavir Mesylate) 1250 Mg Bid, Crixivan (Indinavir Sulfate) 1200Mg Q12H, And Sustiva (Efavirenz; Dmp-266) 600 Mg Q24H For The Treatment Of Hiv-1 Infection In Non-Nucleoside Re... | 0.92 | 0.51 | 2,061 | 0.739493 |
NCT00002240 | listed | BRISTOL MYERS SQUIBB | Bristol-Myers Squibb | Evaluation Of The Safety And Antiviral Efficacy Of A Novel Hiv-1 Protease Inhibitor, Bms-232632, Alone And In Combination With D4T And Ddi As Compared To A Reference Combination Regimen | 0.95 | 0.77 | 760 | 0.859833 |
NCT00002246 | listed | Bristol-Myers Squibb | Bristol-Myers Squibb | A Pilot Open Label, Multicenter Study to Evaluate the Role of Stavudine (d4T) in the Treatment of AIDS Dementia Complex | 0.93 | 0.76 | 2,965.48 | 0.872261 |
NCT00002261 | listed | BRISTOL MYERS SQUIBB | Bristol-Myers Squibb | A Comparative Phase I Clinical Study Of Hivac-1E And Smallpox (Vaccinia) Vaccines In Previously (Vaccinia) Vaccinated And Unvaccinated Volunteers | 0.32 | 0.15 | 2,885 | 0.241333 |
NCT00002274 | listed | BRISTOL MYERS SQUIBB | Bristol-Myers Squibb | An Open Label Study Regimen Of Videx (2',3'-Dideoxyinosine, Ddi) In Patients With Acquired Immunodeficiency Syndrome (Aids) Exhibiting Significant Deterioration While Taking Zidovudine (Retrovir) | 0.56 | 0.48 | 2,891 | 0.473438 |
NCT00002275 | listed | Abbott | Abbott | Lipid-Based Parenteral Nutritional Support In Patients With The Acquired Immunodeficiency Syndrome And Pneumocystis Carinii Pneumonia. A Comparison Of Two Lipid Formulations | 0.63 | 0.34 | 3,398 | 0.461827 |
NCT00002280 | listed | BRISTOL MYERS SQUIBB | Bristol-Myers Squibb | An Open Label Study Regimen Of Videx (2',3'-Dideoxyinosine, Ddi) In Children With Acquired Immunodeficiency Syndrome (Aids) Who Have Demonstrated Significant Deterioration Or Intolerance To Zidovudine (Retrovir) | 0.8 | 0.33 | 615 | 0.582194 |
NCT00002293 | listed | BRISTOL MYERS SQUIBB | Bristol-Myers Squibb | Nystatin Pastille For The Prophylaxis Of Oral Candidiasis In Patients With Aids Or Aids Related Syndromes | 0.63 | 0.37 | 2,891 | 0.475719 |
NCT00002300 | listed | BRISTOL MYERS SQUIBB | Bristol-Myers Squibb | Phase Ii-Iii Randomized Double-Blind Study Comparing Megestrol Acetate At 100, 400, And 800 Mg/Day, And Placebo In Aids Patients With Anorexia And Cachexia | 0.92 | 0.64 | 2,891 | 0.777242 |
NCT00002307 | listed | BRISTOL MYERS SQUIBB | Bristol-Myers Squibb | A Double-Blind Comparison Of Zidovudine (Azt) Versus Stavudine (D4T; Bmy 27857) For The Treatment Of Patients With Hiv Infection Who Have Absolute Cd4 Lymphocyte Counts Between 50 And 500 Cells/Mm3 | 0.94 | 0.8 | 615 | 0.822764 |
NCT00002308 | listed | BRISTOL MYERS SQUIBB | Bristol-Myers Squibb | A Randomized Blinded Evaluation Of Two Doses Of Stavudine (2',3'-Didehydro-2',3'-Dideoxythymidine; D4T) To Make Treatment Available To Severely Immunocompromised Patients With Hiv Infection Who Have Failed Or Are Intolerant Of Alternative Antiretroviral Therapy | 0.73 | 0.55 | 4,294 | 0.584856 |
NCT00002331 | listed | Abbott | Abbott | A Randomized Open-Label Study Of The Tolerability And Efficacy Of Clarithromycin And Ethambutol In Combination With Or Without Clofazimine For The Treatment Of Disseminated Mac (Dmac) In Patients With Aids | 0.95 | 0.57 | 5,554 | 0.709893 |
NCT00002336 | listed | Abbott | Abbott | A Prospective, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of The Safety And Efficacy Of Clarithromycin For The Prevention Of Disseminated Mycobacterium Avium Complex (Mac) Infection In Hiv-Infected Patients With Cd4 Counts <= 100 Cells/Mm3 | 0.95 | 0.56 | 5,554 | 0.706473 |
NCT00002345 | listed | BRISTOL MYERS SQUIBB | Bristol-Myers Squibb | Phase Iv Study On The Safety And Efficacy Of Megace Oral Suspension In Hiv-Positive Females | 0.93 | 0.63 | 2,891 | 0.849685 |
NCT00002348 | listed | SANOFI | Sanofi | Phase Ii Evaluation Of Mitoguazone Dihydrochloride In Patients With Refractory Or Relapsed Non-Hodgkin'S Lymphoma Associated With Acquired Immunodeficiency Syndrome | 0.48 | 0.2 | 7,718 | 0.365457 |
NCT00002349 | listed | BRISTOL MYERS SQUIBB | Bristol-Myers Squibb | A Pilot Study To Compare The Antiviral And Immunologic Effects Of Stavudine ( D4T ) Versus Placebo In Subjects With Evidence Of Recent Hiv Infection. | 0.93 | 0.77 | 4,181 | 0.774816 |
NCT00002352 | listed | BRISTOL MYERS SQUIBB | Bristol-Myers Squibb | Pilot Study Of The Antiviral Activity Of Multiple Doses Of Oral Lobucavir In Aids Patients | 0.93 | 0.55 | 2,891 | 0.708307 |
NCT00002358 | listed | BRISTOL MYERS SQUIBB | Bristol-Myers Squibb | Open-Label Bv-Arau Treatment Of Pediatric Hiv-Infected Patients With Cutaneous, Visceral, Or Ocular Varicella-Zoster Viral Disease Who Have Failed Or Are Intolerant Of Standard Therapy | 0.35 | 0.17 | 2,891 | 0.309083 |
NCT00002360 | listed | BRISTOL MYERS SQUIBB | Bristol-Myers Squibb | Pivotal Bioequivalence Study Of Videx Chewable/Dispersible Buffered Tablets And An Encapsulated Enteric Coated Bead Formulation Of Didanosine In Hiv-Infected Subjects | 0.91 | 0.75 | 731 | 0.804305 |
NCT00002366 | listed | Abbott | Abbott | A Phase Ii Safety And Activity Study Of Ritonavir In The Treatment Of Hiv-Associated Cutaneous Kaposi'S Sarcoma | 0.39 | 0.18 | 3,398 | 0.314135 |
NCT00002369 | listed | BRISTOL MYERS SQUIBB | Bristol-Myers Squibb | An Open Label, Randomized, Comparative Study Of Zerit (D4T) + Epivir (3Tc) + Crixivan Versus Retrovir (Azt) + Epivir (3Tc) + Crixivan In Hiv-Infected, Antiretroviral Naive Subjects With Cd4 Cell Counts Of 200 - 700 Cells/Mm3 And Hiv Rna Baseline Copy Number Of >= 10,000 Copies/Ml | 0.93 | 0.6 | 2,891 | 0.725409 |
NCT00002371 | listed | BRISTOL MYERS SQUIBB | Bristol-Myers Squibb | A Randomized Double-Blind Study Of Safety, Virologic And Immunological Effects Of Stavudine Plus Lamivudine (3Tc) Versus Zidovudine Plus Lamivudine In Hiv-Infected Subjects Following At Least Six Months Of Zidovudine Therapy | 0.96 | 0.85 | 1,062 | 0.90641 |
NCT00002411 | listed | BRISTOL MYERS SQUIBB | Bristol-Myers Squibb | A Randomized Study Of The Long-Term Suppression Of Plasma Hiv Rna Levels By Triple Combination Regimens In Treatment Naive Subjects | 0.94 | 0.78 | 4,192 | 0.783869 |
NCT00002418 | listed | Bristol-Myers Squibb | Bristol-Myers Squibb | A Phase II, 24-Week, Open-Label Study Designed to Evaluate the Pharmacokinetics, Safety, Tolerability, and Efficacy of Novel Combination Therapy With Videx (Didanosine), Zerit (Stavudine), Viramune (Nevirapine), and MKC-442 (With or Without Hydroxyurea) for the Treatment of HIV-1 Infection in Non-Nucleoside Reverse Tra... | 0.08 | 0.18 | 2,491.31 | 0.147075 |
NCT00002419 | listed | DuPont Industrial Biosciences USA, LLC | Dupont Applied Biosciences | A Phase Ii, 24-Week, Open-Label Study Designed To Evaluate The Safety, Tolerability, And Efficacy Of Novel Quadruple-Combination Therapy With Preveon (Adefovir Dipivoxil; Bis-Pom Pmea), Abacavir (1592U89), Sustiva (Efavirenz; Dmp-266), And Amprenavir (141W94) For The Treatment Of Hiv-1 Infection In Patients Who Have Fa... | 0.93 | 0.52 | 2,061 | 0.747071 |
NCT00002420 | listed | PHARMACIA AND UPJOHN COMPANY | Pharmacia and Upjohn | A Phase Ii, 24-Week, Open-Label Study Designed To Evaluate The Pharmacokinetics, Safety, Tolerability, And Efficacy Of Novel Combination Therapy With Videx (Didanosine), Zerit (Stavudine), Rescriptor (Delavirdine Mesylate), And Mkc-442 (With Or Without Hydroxyurea) For The Treatment Of Hiv-1- Infected Patients Who Fail... | 0.08 | 0.1 | 3,208 | 0.111376 |
NCT00002429 | listed | BRISTOL MYERS SQUIBB | Bristol-Myers Squibb | Evaluation Of Hiv Rna Suppression Produced By A Triple Combination Regimen Containing An Enteric Coated Formulation Of Didanosine (Ddi Ec) Administered Once Daily Compared To A Reference Combination Regimen | 0.96 | 0.74 | 4,192 | 0.842981 |
NCT00002439 | listed | Ligand Pharmaceuticals | Ligand Pharmaceuticals | Randomized Phase Iii Vehicle Controlled Trial Of Alrt 1057 Topical Gel In Patients With Aids-Related Kaposi'S Sarcoma | 0.62 | 0.08 | 2,061 | 0.383317 |
NCT00002663 | listed | Atara Biotherapeutics Inc | Atara Biotherapeutics | An Evaluation Of The Toxicity And Therapeutic Effects Of Epstein-Barr Virus-Immune T-Lymphocytes Derived From A Normal Hla-Compatible Or Haplotype-Matched Donor In The Treatment Of Ebv-Associated Lymphoproliferative Diseases Or Malignancies And Patients With Detectable Circulating Levels Of Ebv Dna Who Are At High Risk... | 0.94 | 0.76 | 8,888 | 0.805348 |
NCT00002664 | listed | GW | George Washington University | Phase Ii Study Of Monoclonal Antibody 17-1A With Gm-Csf In Treatment Of 5-Fu Resistant Colorectal Cancer | 0.1 | 0.5 | 6,464 | 0.240529 |
NCT00002837 | listed | BRISTOL MYERS SQUIBB | Bristol-Myers Squibb | Phase I-Ii Study Of Dose Intense Doxorubicin, Paclitaxel And Cyclophosphamide With Peripheral Blood Progenitor Cells (Pbpc) And Cytokine Support In Patients With Metastatic Breast Cancer | 0.95 | 0.59 | 4,656 | 0.765633 |
NCT00002848 | listed | Rochester | University of Rochester | Supportive-Expressive Group Therapy For Men With Primary Prostate Cancer | 0.96 | 0.51 | 4,873 | 0.698858 |
NCT00002850 | listed | Rochester | University of Rochester | Oral Antibiotic Prophylaxis Of Early Infection In Multiple Myeloma | 0.95 | 0.53 | 4,444 | 0.763913 |
NCT00002956 | listed | UAB "AGA" | University of Alabama at Birmingham | A Phase I Pilot Trial To Evaluate The Toxicity Of Allogeneic Epstein-Barr Virus Specific T-Lymphocytes For The Treatment Of Ebv-Associated Lymphoproliferative Diseases In Organ Transplant Recipients | 0.11 | 0.5 | 5,985 | 0.222355 |
NCT00002960 | delisted | Merck Sharp & Dohme L.L.C. | Merck Sharp & Dohme LLC | A Phase I Study In Patients With Peritoneal Carcinomatosis Using Sch 58500 (Rad/P53) Administered By Single Intraperitoneal Instillation | 0.94 | 0.53 | 243 | 0.755344 |
NCT00002973 | listed | Madison | University of Wisconsin, Madison | Phase Ii Evaluation Of Iv Melphalan (L-Pam) And Whole Body Hyperthermia (Wbh) For Malignant Melanoma | 0.94 | 0.51 | 5,814 | 0.726138 |
NCT00002974 | listed | Madison | University of Wisconsin, Madison | A Phase Ii Study Of Whole Blood Hyperthermia And Ice Chemotherapy In Sarcoma Patients | 0.94 | 0.51 | 7,347 | 0.718543 |
NCT00003056 | listed | TAKEDA PHARMACEUTICAL CO LTD | Takeda | Peripheral Blood Stem Cell Transplantation In Patients With Advanced Malignancies Eligible For Allogeneic Transplantation From Matched Related Donors: A Randomized Study Of Cyclosporine/Methotrexate Or Cyclosporine/T-Cell Depletion (Cd34 Cell Selection) For Gvhd Prophylaxis | 0.11 | 0.5 | 7,857 | 0.257158 |
NCT00003126 | listed | Chiron Corporation | Chiron Corporation | A Randomized Controlled Phase Iii Adjuvant Trial Of High-Dose Bolus Il-2 In Patients With High-Risk Renal Cell Carcinoma | 0.94 | 0.56 | 6,274 | 0.758406 |
NCT00003131 | listed | Pfizer | Pfizer | A Study Of The Efficacy And Safety Of Cma-676 As Single Agent Treatment Of Patients With Acute Myeloid Leukemia (Aml) In First Relapse | 0.96 | 0.71 | 823 | 0.844113 |
NCT00003219 | listed | Madison | University of Wisconsin, Madison | A Phase Ii Trial Of Perillyl Alcohol (Nsc 641066) Administered Daily In Patients With Metastatic Breast Cancer | 0.88 | 0.51 | 1,095 | 0.726566 |
NCT00003225 | listed | ALZA Corporation | ALZA | Phase I/Ii Trial To Evaluate Ethyol As A Protective Agent For Irinotecan (Cpt-11) Toxicities In Patients With Advanced Colorectal Cancer | 0.95 | 0.61 | 578 | 0.807936 |
NCT00003238 | listed | Madison | University of Wisconsin, Madison | A Phase Ii Trial Of Perillyl Alcohol (Nsc 641066) Administered Daily In Patients With Metastatic Androgen Independent Prostate Cancer | 0.92 | 0.5 | 700 | 0.751271 |
NCT00003269 | delisted | Scripps NP Operating, LLC | Scripps Health | A Phase Ii, Open-Label, Trial Evaluating The Efficacy Of Amifostine In Patients With Cancers Receiving Outpatient Dose-Intensive Cyclophosphamide, Etoposide, And Cisplatin (Dicep) Chemotherapy | 0.94 | 0.52 | 4,088 | 0.741555 |
NCT00003293 | listed | Pfizer | Pfizer | A Phase Iii Randomized Study Of Su101 Versus Procarbazine For Patients With Glioblastoma Multiforme In First Relapse | 0.96 | 0.7 | 4,698 | 0.826253 |
NCT00003337 | listed | Gilead Sciences | Gilead Sciences | The Utility Of Lymphoscan Imaging In The Localization And Staging Of Patients With Non-Hodgkin'S Lymphoma | 0.91 | 0.49 | 7,959 | 0.72034 |
NCT00003338 | listed | Gilead Sciences | Gilead Sciences | The Utility Of Lymphoscan Imaging In The Dectection Of Residual Tumor After Chemotherapy And/Or Radiotherapy In Patients With Non-Hodgkin'S Lymphoma | 0.91 | 0.5 | 7,959 | 0.723786 |
NCT00003343 | listed | Pfizer | Pfizer | A Randomized, Double-Blind, Placebo-Controlled, Phase Iii Study Of The Matrix Metalloprotease Inhibitor Ag3340 In Combination With Mitoxantrone And Prednisone With Provision For Subsequent Change In Therapy In Patients Having Hormone-Refractory Prostate Cancer | 0.32 | 0.21 | 4,664 | 0.294006 |
NCT00003356 | listed | Rochester | University of Rochester | A Phase Ii Study Of Rituxan And Il-2 In Patients With Low Grade Or Follicular B-Cell Lymphoma | 0.94 | 0.5 | 5,098 | 0.726609 |
NCT00003405 | listed | Rush Specialty Hospital, LLC | Rush University Medical Center | Treatment Protocol For Patients With Standard Risk Acute Myelogenous Leukemia And Its Variants: Induction Using High-Dose Cytarabine, Mitoxantrone And Ethyol; Consolidation With Cytarabine And Idarubicin And Maintenance With 13 Cis Retinoic Acid And Alpha Interferon | 0.12 | 0.29 | 8,018 | 0.172764 |
NCT00003407 | listed | Rush Specialty Hospital, LLC | Rush University Medical Center | Treatment Of Poor Prognosis Acute Myeloid Leukemia And Blastic Crisis Chronic Myelogenous Leukemia With Mylotarg, High-Dose Cytarabine, Mitozantrone And Ethyol Aml/Cml 2000-06. | 0.15 | 0.51 | 8,494 | 0.263013 |
NCT00003450 | listed | UT Southwestern DVA Healthcare, L.L.P. | University of Texas Southwestern Medical Center | Phase I Trial Of Intraperitoneal Adenoviral P53 Gene Therapy In Patients With Advanced Recurrent Or Persistent Ovarian Cancer | 0.94 | 0.5 | 731 | 0.735896 |
NCT00003563 | listed | Pharmacyclics LLC | Pharmacyclics LLC. | Phase Iii Randomized Trial Of Gadolinium Texaphyrin (Pci-0120) Injection As A Radiation Sensitizer In Patients Receiving Whole Brain Radiation Therapy For The Treatment Of Brain Metastases | 0.96 | 0.56 | 5,113 | 0.775989 |
NCT00003622 | listed | GW | George Washington University | Phase Ii Study Of Vinorelbine With Paclitaxel In The Treatment Of Hormone-Refractory Prostate Cancer | 0.1 | 0.5 | 6,323 | 0.241236 |
NCT00003645 | listed | ASTRAZENECA PLC | AstraZeneca | A Phase Iii Randomized Prospective Trial Of Adjuvant Hormonal Therapy In Surgically Treated Prostate Cancer Patients At High Risk For Recurrence | 0.14 | 0.54 | 6,349 | 0.29513 |
NCT00003669 | listed | ELI Lilly AND COMPANY | Eli Lilly and Company | Phase Ii Nonrandomized Study Of Ly353381-Hc1 In Patients With Recurrent Or Advanced Endometrial Cancer | 0.95 | 0.65 | 4,602 | 0.786474 |
NCT00003670 | listed | ELI Lilly AND COMPANY | Eli Lilly and Company | Phase Ii Study Of Ly353381-Hc1 Administered To Women With Refractory Ovarian Cancer | 0.96 | 0.66 | 427 | 0.833449 |
NCT00003673 | listed | Pfizer | Pfizer | A Study Of The Safety Of Cma-676 In Treatment Of Elderly Patients With Acute Myeloid Leukemia (Aml) In First Relapse | 0.97 | 0.71 | 1,095 | 0.84628 |
NCT00003712 | listed | Wyeth Pharmaceuticals Company | Wyeth is now a wholly owned subsidiary of Pfizer | A Phase I Study Of The Safety, Tolerability, And Pharmacokinetics Of Intravenous Cci-779 Given Once Daily For 5 Days Every 2 Weeks To Patients With Advanced Solid Tumors | 0.94 | 0.64 | 4,665 | 0.750671 |
NCT00003713 | listed | SANOFI | Sanofi | A Phase I, Pharmacokinetic, And Treatment Duration And Escalation Study Of Intravenous Intoplicine Administered As A 5 To 21-Day Continuous Infusion Every 4 Weeks | 0.91 | 0.55 | 6,876 | 0.707594 |
NCT00003720 | listed | Pfizer | Pfizer | A Multicenter, Dose Escalating Study In Patients With Cutaneous Aids-Related Kaposi'S Sarcoma | 0.92 | 0.65 | 4,679 | 0.742608 |
NCT00003748 | listed | PHARMACIA AND UPJOHN COMPANY | Pharmacia and Upjohn | Phase Ii Study Of Irinotecan (Cpt-11) In Adenocarcinoma Of The Esophagus And Gastric Cardia | 0.95 | 0.59 | 7,581 | 0.75052 |
NCT00003760 | delisted | Merck Sharp & Dohme L.L.C. | Merck Sharp & Dohme LLC | A Phase Ii Trial Of Mgi 114 In Patients With Advanced Pancreatic Adenocarcinoma | 0.95 | 0.62 | 182 | 0.819823 |
NCT00003763 | listed | ENDOCYTE, INC. | Endocyte | A Study To Determine The Ability Of Folate Conjugates To Target Folate Receptors In Ovarian Cancer Tumors | 0.96 | 0.51 | 877 | 0.736769 |
NCT00003775 | listed | Pfizer | Pfizer | A Phase Ii Open Label Study Of Su101 For Patients With Anaplastic Astrocytoma In First Relapse | 0.96 | 0.68 | 4,700 | 0.80186 |
NCT00003817 | listed | Rochester | University of Rochester | A Randomized Phase Ii Trial Of Acupressure And Acustimulation Wrist Bands For The Prevention Of Chemotherapy-Induced Nausea And Vomiting | 0.94 | 0.51 | 5,827 | 0.72607 |
NCT00003821 | listed | SANOFI | Sanofi | Phase Ii Trial Of Aminopterin In Patients With Persistent Or Recurrent Endometrial Carcinoma | 0.12 | 0.07 | 6,896 | 0.118164 |
NCT00003822 | listed | SANOFI | Sanofi | A Phase I And Pharmacokinetic Study Of Sr-45023A During A 14-Day Treatment Schedule | 0.32 | 0.1 | 6,876 | 0.216389 |
NCT00003847 | listed | VERTEX PHARMACEUTICALS INCORPORATED | Vertex Pharmaceuticals Incorporated | A Phase Ii Study Of The Safety, Efficacy And Pharmacokinetics Of Vx-710 In Combination With Doxorubicin And Vincristine In Patients With Small Cell Lung Cancer (Sclc) | 0.12 | 0.34 | 5,057 | 0.204655 |
NCT00003865 | listed | GW | George Washington University | Phase Ii Study Of Two Dose Levels Of Toremifene In The Treatment Of Chemotherapy-Resistant Papillary Carcinoma Of The Ovary | 0.12 | 0.5 | 6,425 | 0.252125 |
NCT00003880 | delisted | Merck Sharp & Dohme L.L.C. | Merck Sharp & Dohme LLC | A Phase Ii/Iii Trial Of Chemotherapy Alone Versus Chemotherapy Plus Sch 58500 In Newly Diagnosed Stage Iii Ovarian And Primary Peritoneal Cancer Patients With Greater Than Or Equal To 0.5 Cm And Less Than Or Equal To 2 Cm Residual Disease Following Surgery | 0.08 | 0.18 | 5,645 | 0.14144 |
NCT00003884 | listed | NOVARTIS AG | Novartis | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial To Evaluate The Safety And Efficacy Of Zoledronate (4 And 8 Mg) Administered Intravenously As An Adjuvant To Anticancer Therapy To Patients With Any Cancer With Bone Metastases Other Than Breast Cancer, Multiple Myeloma Or Prostate Cancer | 0.96 | 0.58 | 4,861 | 0.784262 |
NCT00003891 | listed | NeXstar Pharmaceuticals, Inc. | Nexstar Pharmaceuticals | A Phase I Study Of Nx211 Given As An Iv Infusion Days 1, 2 And 3 Every 3 Weeks In Patients With Solid Tumors | 0.93 | 0.66 | 7,714 | 0.747145 |
NCT00003897 | listed | Madison | University of Wisconsin, Madison | Phase I Trial Of Immunization Using Particle-Mediated Transfer Of Genes For Gp-100 And Gm-Csf Into Uninvolved Skin Of Patients With Melanoma (Summary Last Modified 7/1999) | 0.94 | 0.5 | 7,323 | 0.688924 |
NCT00003903 | listed | Rochester | University of Rochester | An Evaluation Of The Effect Of Androgen Ablation On Bone Resorption In Prostate Cancer Patients | 0.82 | 0.03 | 5,098 | 0.453589 |
NCT00003906 | listed | ASTRAZENECA PLC | AstraZeneca | Study Of Tamoxifen And Raloxifene (Star) For The Prevention Of Breast Cancer | 0.95 | 0.82 | 4,657 | 0.861838 |
NCT00003966 | listed | JAZZ PHARMACEUTICALS INC | Jazz Pharmaceuticals | Defibrotide For Hematopoietic Stem Cell Transplant Patients With Severe Hepatic Venocclusive Disease: A Phase I/Ii Study To Determine The Minimal Effective Dose | 0.94 | 0.66 | 6,290 | 0.774989 |
NCT00004016 | listed | Rochester | University of Rochester | Phase I Trial Of Immunotherapy With Adenovirus-Interferon- Gamma (Tg1041) In Patients With Malignant Melanoma | 0.34 | 0.07 | 4,966 | 0.211924 |
NCT00004049 | listed | SANOFI | Sanofi | A Phase I And Pharmacokinetic Study Of Sr-45023A Administered Once Every 7 Days | 0.33 | 0.11 | 6,837 | 0.225668 |
NCT00004071 | listed | Pfizer | Pfizer | A Randomized, Open-Label Phase Ii/Iii Study Of Su101 Plus Mitoxantrone/Prednisone Compared To Mitoxantrone/Prednisone Alone In Patients With Hormone-Refractory Prostate Cancer | 0.96 | 0.7 | 2,822 | 0.838626 |
NCT00004159 | listed | UAB "AGA" | University of Alabama at Birmingham | Biweekly Gemcitabine And Paclitaxel In Patients With Advanced Non-Small Cell Lung Cancer And Solid Tumors: A Phase I/Iia Study | 0.11 | 0.5 | 5,094 | 0.253473 |
NCT00004160 | listed | UAB "AGA" | University of Alabama at Birmingham | Sequential And Concomitant Chemoradiotherapy With Gemcitabine-Based Chemotherapy For Inoperable Stage Iiia And Iiib Non-Small Cell Lung Cancer: A Phase I/Iia Study | 0.95 | 0.51 | 5,100 | 0.735719 |
NCT00004161 | listed | UAB "AGA" | University of Alabama at Birmingham | A Randomized, Double Blind, Placebo-Controlled Phase Ii Clinical Trial Of N(4-Hydroxy-Phenyl)Retinamide (Fenretinide, 4Hpr) In Oral Leukoplakia | 0.94 | 0.51 | 4,872 | 0.731314 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.